THE ADMINISTRATION OF BAS, 5-HTP, AND MARSILID TO SCHIZOPHRENIC PATIENTS
Abstract
The administration to 5 chronic schizophrenic patients of BAS alone, of BAS and 5-HTP combined, and of BAS and 5-HTP in conjunction with Marsilid was not therapeutically useful. The fact that the patients did not react to the presumed increase in brain serotonin casts doubt upon the hypothesis that too little or too much serotonin is causally related to schizophrenia.
BAS appears to be a monoamine oxidase inhibitor. The conversion of 5-HTP to 5-HIAA was thus prevented resulting in an accumulation of serotonin in urine.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
